Indian Pharmacopoeia Commission

What Indian Pharmacopoeia Commission does

Indian Pharmacopoeia Commission (IPC) is an autonomous institution under India's Ministry of Health & Family Welfare that operates as the national standard-setting authority for drugs, pharmaceutical aids, and biological products. Headquartered in Ghaziabad, IPC publishes the Indian Pharmacopoeia (IP) and the National Formulary of India (NFI), produces IP Reference Substances (IPRS) used in regulatory testing, and runs three national safety monitoring programmes — the Pharmacovigilance Programme of India (PvPI), the Materiovigilance Programme (MvPI), and the Haemovigilance Programme of India (HvPI) — supported by a network of more than 250 Adverse Drug Reaction Monitoring Centres.

Beyond publications, IPC operates central and regional drug testing laboratories that provide analytical services to manufacturers and regulators, and issues standards and guidance that are referenced under the Drugs and Cosmetics Act, 1940. The commission is also designated as a WHO Collaborating Centre for Safety of Medicines and Vaccines — the first in South-East Asia — and exports IP volumes to international regulators and manufacturers.

IPC's revenue model is a hybrid of central-government budgetary grants (primary) and earned income from publication sales, IP Reference Substance distribution, and laboratory testing/certification services. Its stakeholder base spans the Central Drugs Standard Control Organisation (CDSCO), state drug controllers, pharmaceutical manufacturers, healthcare professionals, academic institutions, and patients (indirectly, through safety monitoring outputs). IPC has no equity funding, no PE/VC backing, and no M&A activity; growth is driven by government programme mandates, periodic pharmacopoeia updates, and partnership extensions (most recently three MoUs signed in February 2026 with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services).

Name

Indian Pharmacopoeia Commission

Legal name

Indian Pharmacopoeia Commission

Website

https://ipc.gov.in

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

251–500 employees

Short description

The Indian Pharmacopoeia Commission is an autonomous government body that sets national drug quality standards, publishes the Indian Pharmacopoeia, and operates national pharmacovigilance programmes serving regulators, pharmaceutical manufacturers, and healthcare professionals in India.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Standards

NAICS

Pharmaceutical Preparation Manufacturing (325412), Testing Laboratories and Services (54138), Other Scientific and Technical Consulting Services (541690), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

National Public Health Reference Laboratories (HLAJAIAA)

Keywords

• Pharmacopoeial standards
• Drug safety monitoring
• Reference substances
• Pharmacovigilance programme
• Pharmaceutical quality control

Headquarters

HQ city

Ghaziabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Government Funding: IPC operates as an autonomous body under Ministry of Health & Family Welfare, Government of India, primarily funded through government budgets
2. Publication Sales: Sale of Indian Pharmacopoeia (IP), National Formulary of India (NFI), and IP Reference Substances through online shop and offline distribution
3. Certification Services: ICMED certification and other quality certification services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

IPC publishes the Indian Pharmacopoeia (IP) and National Formulary of India (NFI) as official drug quality standards, supplies IP Reference Substances (IPRS) used as authenticity fingerprints for drug testing, and operates national drug safety monitoring programmes (PvPI, MvPI, HvPI) through 250+ ADR Monitoring Centres. It also offers NABL-accredited analytical testing via the Indian Pharmacopoeia Laboratory (IPL), ICMED certification, and pharmacovigilance skill development programmes.

Product overview

The Indian Pharmacopoeia Commission (IPC) operates as a platform-plus-services model. The core products are the Indian Pharmacopoeia (IP) and National Formulary of India (NFI) — official publications that set legally binding quality standards for drugs in India. These are supported by IP Reference Substances (IPRS) and Impurity Standards, which are authenticated reference materials required for pharmaceutical testing. IPC also operates three safety monitoring programmes: Pharmacovigilance Programme of India (PvPI), Materiovigilance Programme of India (MvPI), and Haemovigilance Programme of India (HvPI) for tracking adverse events with drugs, medical devices, and blood products respectively. Additional offerings include IP Online (digital access platform), Indian Pharmacopoeia Laboratory (analytical testing services), ICMED Certification, and Skill Development Training programmes. The portfolio is unified by IPC's mandate to ensure quality, safety, and efficacy of pharmaceutical products in India.

Differentiator

Problem solved

Functional benefit

Brands

• Pharmacovigilance Programme of India (PvPI): A flagship drug safety monitoring programme of Government of India that collects, collates and analyses drug-related adverse events through various ADR monitoring centres.
• Materiovigilance Programme of India (MvPI)
• Haemovigilance Programme of India (HvPI)
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• IP Reference Substances (IPRS)

Products and services

• Indian Pharmacopoeia (IP) Official pharmacopoeial standards document published by IPC that sets quality standards for drugs, pharmaceuticals, and biologics marketed in India. It has legal status under the Drugs and Cosmetics Act, 1940 and serves as the authoritative reference for drug identification, purity, and strength.
• National Formulary of India (NFI) Publication providing guidance on rational use of generic medicines for healthcare professionals including clinicians, pharmacists, nurses, and medical students. It contains approved drug formulations based on therapeutic considerations and current medical practices.
• IP Reference Substances (IPRS) and Impurity Standards Authenticated chemical reference substances issued by IPC used as finger-print standards for identification and purity testing of pharmaceutical articles as per IP monographs. Includes chemical reference substances, biological reference substances, IP reference spectra, botanical reference substances, and reference microbial cultures.
• Pharmacovigilance Programme of India (PvPI) National drug safety monitoring programme that collects, collates, and analyzes adverse drug reactions (ADRs) from over 250 ADR Monitoring Centres across India. Contributes data to the WHO Global ADR database and advises CDSCO on drug safety regulatory actions.
• Materiovigilance Programme of India (MvPI) Medical device safety monitoring programme that collects and analyzes adverse events associated with medical devices. Operates through Medical Device Monitoring Centres (MDMCs) to improve patient safety related to medical devices in India.
• Haemovigilance Programme of India (HvPI) Blood safety monitoring programme coordinated by National Institute of Biologicals (NIB) that tracks adverse events related to blood transfusion to ensure blood product safety in India.
• IP Online Platform Online subscription platform for accessing Indian Pharmacopoeia digital content, enabling pharmaceutical companies, regulatory bodies, and healthcare professionals to access pharmacopoeial standards electronically.
• Indian Pharmacopoeia Laboratory (IPL) Analytical Testing Services NABL-accredited laboratory providing new drugs testing services and analytical support for skill development and drug discovery. Located at IPC, Ghaziabad.
• ICMED Certification Inspection and certification service for pharmaceutical and healthcare facilities ensuring compliance with quality standards and regulatory requirements.
• Pharmacovigilance Skill Development Programme Capacity building programmes on pharmacovigilance, analytical testing, and drug quality assurance conducted by IPC for pharmaceutical professionals, healthcare workers, and regulatory personnel.

Quantifiable outcome

• 250+ ADR Monitoring Centres operational across India
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and flagship.

• Goa State Pharmacy CouncilcoreStrategic or Co-development Partner · 9 February 2026MoU signed to strengthen drug safety, quality assurance, and capacity-building initiatives. Establishes framework for collaboration in pharmacovigilance, ADR reporting, training programmes, and awareness initiatives promoting uniform standards for medicine quality and patient safety across India.
• Quality Council of IndiacoreStrategic or Co-development Partner · 9 February 2026MoU signed for collaboration in pharmacovigilance, quality assurance training, and standardization initiatives. Joint efforts to promote uniform standards for medicine quality and patient safety across India.
• HLL Infra Tech Services LimitedcoreStrategic or Co-development Partner · 9 February 2026MoU for infrastructure and capacity-building initiatives supporting pharmacovigilance programme and training activities.
• World Health Organization (WHO)flagshipStrategic or Co-development Partner · 4 November 2015IPC designated as first WHO Collaborating Centre for Safety of Medicines and Vaccines in South-East Asia Region. Active participation in WHO Programme for International Drug Monitoring, contributing to global ADR database through Uppsala Monitoring Centre, Sweden.
• WHO Uppsala Monitoring Centre, SwedencoreTechnology or Integration · 4 November 2015Global ADR database collaboration for international drug monitoring. India's pharmacovigilance data contributed to WHO's global safety database.
• NABH (National Accreditation Board for Hospitals)coreStrategic or Co-development Partner · 1 January 2015MoU between IPC, NCC-PvPI and NABH for collaboration in hospital accreditation and pharmacovigilance integration.
• CDSCO (Central Drugs Standard Control Organization)coreImplementation/ SI/ Consulting PartnerPvPI provides recommendations to CDSCO for regulatory actions on drug safety issues. NCC-PvPI assists India's regulatory authority in decision-making for safe use of medicines.
• National Institute of Biologicals (NIB), NoidacoreStrategic or Co-development PartnerReference Standard Biotech Product available at NIB, Noida. Collaborative haemovigilance programme (HvPI) coordination.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• National Institute of Biologicals (NIB): NIB operates in parallel to IPC as a government biological reference laboratory under India's health ministry, coordinating the Haemovigilance Programme of India (HvPI) and housing biological reference standards. Directly comparable peer in India's national drug quality infrastructure.
• Japanese Pharmacopoeia (PMDA): The Japanese Pharmacopoeia is established under Japan's Pharmaceuticals and Medical Devices Act and sets official drug quality standards. Operates in a similar national pharmacopoeia capacity as IPC, and is part of the Pharmacopoeial Discussion Group.
• United States Pharmacopeia (USP): USP is the most direct peer: a pharmacopoeial standards-setting body for the United States, publishing the United States Pharmacopeia and National Formulary, and supplying reference standards. Like IPC, USP operates an independent laboratory network and engages in pharmacovigilance and quality assurance activities globally.
• British Pharmacopoeia (MHRA): The British Pharmacopoeia is published by the Medicines and Healthcare products Regulatory Agency (MHRA), setting quality standards for UK pharmaceuticals. Comparable to IPC in publishing national pharmacopoeial standards and reference substances.
• European Pharmacopoeia (EDQM): The European Directorate for the Quality of Medicines & HealthCare sets and publishes the European Pharmacopoeia and provides reference standards for 39 European member states. EDQM is directly comparable to IPC in mandate, structure, and product portfolio.

Broad incumbents

• WHO Collaborating Centre for International Drug Monitoring: The WHO Programme for International Drug Monitoring is the umbrella under which IPC operates as a Collaborating Centre. Comparable in scope of global pharmacovigilance governance and as a partner/incumbent in the international drug safety ecosystem.
• Central Drugs Standard Control Organization (CDSCO): CDSCO is India's national drug regulatory authority under the Ministry of Health & Family Welfare. IPC's PvPI provides recommendations to CDSCO, making it the principal customer and ecosystem incumbent for IPC's safety monitoring outputs.

Emerging players

• WHO Uppsala Monitoring Centre: The WHO Uppsala Monitoring Centre operates the global pharmacovigilance database and collaborates with national pharmacovigilance centres. IPC's PvPI contributes directly to UMC's database, making UMC a strategic partner and peer in safety monitoring infrastructure.

Others

• Pharmacopoeial Discussion Group (PDG): The PDG coordinates harmonization of pharmacopoeial standards across USP, EP, JP, and IPC's Indian Pharmacopoeia. Functions as IPC's standards-harmonization peer forum and signals India's integration into global pharmacopoeial governance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ipcgzb
• YouTubeyoutube.com/channel/UCy_KW0w36ImIwrUPFhNtcMQ?view_as=subscriber
• Facebookfacebook.com/ipcgzb1
• LinkedInlinkedin.com/company/indian-pharmacopoeia-commission

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indian Pharmacopoeia Commission